“…PPARγ activation is regarded as the key mechanism of anticancer effects of glitazones. PPARγ agonists, in most cases, inhibited proliferation and growth of experimental breast, lung, gastrointestinal, liver, pancreatic, ovarian, testicular and urinary system cancers [292,293,294,295,296]. Antitumor properties independent of PPARγ activation were reported too, including the regulation of differentiation, inflammation and apoptosis; however, it is not always possible to determine whether an effect that is independent of PPARγ-regulated transcriptional control is also independent of the presence of PPARγ protein [297,298].…”